P4-236: alzheimer's disease and the microbiome

James M. Hill,Walter J. Lukiw,Christian Clement,Surjyadipta Bhattacharjee,Yuhai Zhao

DOI: https://doi.org/10.1016/j.jalz.2014.07.008

2014-01-01

Abstract:The realization that the human microbiome (HM) is a significant contributor to nutrition, health and disease is a relatively recent one, however, mechanistic studies linking alterations in microbiota to the etiopathology of disease are relatively few. The HM appears to modulate the regulation of multiple neurochemical pathways through a complex series of highly interactive and symbiotic host-microbiome signaling-systems that mechanistically link the gastrointestinal (GI) tract to the central nervous system (CNS), the enteric nervous system and the neuroendocrine and immune systems.Varying combinations of GI tract bacterial species amongst human populations (i.e. different ' enterotypes') contribute to the idea of ' human-biochemical-individuality' and differential susceptibility to disease. In these preliminary studies we evaluated the effects of the anti-amyloid, anti-oxidant, anti-inflammatory flavonoid quercetin on growth inhibition of the HM-representative Bacteroides galacturonicus (ATCC 43244). Increases in B. galacturonicus in the GI tract have been associated with high fat-cholesterol (HF-C) diets, insulin resistance, diabetes and systemic inflammation. These studies are the first directly linking a major component of the HM to pathological mechanisms associated with Alzheimer's disease (AD), a progressive inflammatory neurodegeneration of the human CNS. Aβ-peptide assay; B.galacturonicus culture; cell-viability assay; minimal inhibitory-concentration (MIC) assay; human neuronal-glial (HNG) primary co-culture; reactive-oxygen-species (ROS) assay; 5-6-carboxy-2',7'-dichloro-fluorescein diacetate (dicarboxy-DCFDA); quercetin assay; RT-PCR; Western immunoassay. Species of the gram negative, obligate anaerobic Bacteroides constitute up to 35% of all HM bacteria, indicating that this genus is a significant component of the HM system. Quercetin was found to strongly inhibit B. galacturonicus proliferation (MIC∼10 μg/ml); using dicarboxy-DCFDA assay quercetin was found to decrease free radical (ROS) production and elicit neuroprotection in stressed HNG cultures. Besides quercetin's anti-oxidant activities this flavonoid may exert beneficial microbiome effects through its inhibition of B. galacturonicus and the homeostatic stabilization the HM. Neuroprotective functions of quercetin and related-flavonoid polyphenols may be to augment or modify the biochemistry or proliferation of HM-resident bacteria such as B. galacturonicus. Bacteroides infections are associated with the release of nucleic acids, lipopolysaccharide (LPS), metalloprotease and other bacterial endotoxins that contribute to amyloidogenesis and inflammatory degeneration. Several additional potential mechanisms by which Bacteroides- mediated alterations in the HM may contribute to AD include molecular-mimicry of host proteins, generation of toxic-metabolites and endotoxins, modification of absorption across the GI tract, and contribution to systemic and/or chronic CNS inflammation in the host, or by complex combinations of these pathogenic processes. In addition to quercetin's anti-amyloid and anti-inflammatory activities this phytochemical may also exert health benefits through inhibition of B. galacturonicus- mediated proliferation of pathological signaling in both the GI tract and the CNS.